Dr. Wurtman will be discussing his findings with the FDA, who currently probably see this information as a "pie in their face" if true.....it points towards the likelihood that Redux used without phentermine, which it was developed for ( as an alternative to the Pondimin-phentermine combo, since it minimized the untoward side effects of taking Pondimin which otherwise was being counteracted with by taking phentermine), and for which 96% of Redux users did just that....that Redux is "safe" and is not to be implicated in this heart valve concern. Of course the initial Redux study, along with tons of anecdotal evidence already points to this.
The news is of far greater importance to IPIC than to AHP, as they have responsiblity not only with Redux, but with Pondimin for which 90% of the usage of the diet drugs was related. The upcoming study from AHP, which evaluates "Redux alone" users with "fen-phen" users has now just gained some greater interest and importance.
I think if this report holds water, it will show that the removal of Redux from the market was unjustified. Whether the companies wish to re-introduce, or the FDA will significantly alter its stance in the matter remains to be seen. But as IPIC was just upgraded by Lehman yesterday on the basis of the recent unveiling of the pagaclone trial, it mentioned that IPIC will remained depressed until the Redux litigation concerns can be better alleviated by the upcoming studies.
The lawsuits will continue, especially as we have the "phentermine companies", those ornary bastards who did not properly label their product, will now get hit hard......but the bent of the lawsuits will change towards the users of the combinational therapy, and the concern of Redux will thus be minimal......the company is not going bankrupt.
Anyone into shorting Medeva or SmithKline now? |
